In 2019, the results of the phase I/II trial, KEYNOTE-021, showed that PD-1 inhibitor pembrolizumab in combination with gefitinib for advanced NSCLC with EGFR mutations was not feasible because of the high occurrence of liver toxicity (71.4%) [71]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.